Yu Yi M. Wong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yu Yi M. Wong has a total of 79 co-authors. Here are the top co-authors by number of shared publications:
- Rinze Frederik Neuteboom
Department of Neurology, Erasmus University Medical Center, Rotterdam, the Netherlands
7 shared publications - Arlette Laurien Bruijstens
Department of Neurology, Erasmus Medical Center, Rotterdam, The Netherlands
4 shared publications A. Verrips
2 shared publicationsE. D. van Pelt
Department of Neurology, MS Centre ErasMS, Erasmus MC, Rotterdam, The Netherlands
2 shared publications- E. Danielle van Pelt
Department of Neurology, Erasmus Medical Center, Room Ee-2230, PO Box 2040, 3000 CA Rotterdam, the Netherlands
2 shared publications F. Visscher
2 shared publications
Latest Publications
- Open Access
- 3 August 2026
- Published by Wiley in European Journal of Neurology
- Vol. 33 (8) , e70723
Update on the Incidence of Paediatric Multiple Sclerosis, Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease, Aquaporin‐4 Antibody–Positive Neuromyelitis Optica Spectrum Disorder, and Other Acquired Demyelinating Syndromes in the Netherlands, 2017–2025, Including the COVID ‐19 Pandemic
Background: Acquired demyelinating syndromes (ADS) in children include multiple sclerosis (MS), myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD), aquaporin 4 antibody‐positive neuromyelitis optica spectrum disorder (AQP4+ NMOSD), and other seronegative disorders. We previously reported an increased incidence of overall paediatric ADS and MS between 2007 to 2010 and 2011–2016 (from 0.66 to 0.80 and 0.15 to 0.26 per 100,000 person‐years, respectively). Environmental factors, including viral exposure, may influence these rates. Comparing a recent period that includes the COVID‐19 pandemic provides an opportunity to study temporal patterns. Methods: Children < 18 years with a first demyelinating event between January 2017 and June 2025 were prospectively included in the nationwide PROUDkids 2.0 study or referred to the Dutch Paediatric MS Centre. Diagnoses followed international criteria, and incidence rates were calculated using national population data. Results: Among 257 included children, 111 (43%) had MS, 93 (36%) MOGAD, 5 (2%) AQP4+ NMOSD, and 48 (19%) seronegative ADS. Overall ADS incidence was 0.91 per 100,000 person‐years, with MS 0.40, MOGAD 0.33, AQP4+ NMOSD 0.02, and seronegative ADS 0.16 per 100,000 person‐years. Compared with 2011–2016 (0.26 per 100,000), MS incidence increased, whereas other ADS rates remained stable. MS incidence declined after COVID‐19 restrictions, particularly among adolescents, while MOGAD incidence rose modestly in younger children during the COVID restrictions. Conclusions: Paediatric MS incidence continues to rise in the Netherlands, whereas the incidence of other ADS remains stable. Temporal variations in the incidence of MS and MOGAD during and after the COVID‐19 pandemic may reflect the influence of viral exposure in their pathogenesis.
- 3 August 2026
- Published by Wiley in European Journal of Neurology
- Vol. 33 (8) , e70723
Open AccessUpdate on the Incidence of Paediatric Multiple Sclerosis, Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease, Aquaporin‐4 Antibody–Positive Neuromyelitis Optica Spectrum Disorder, and Other Acquired Demyelinating Syndromes in the Netherlands, 2017–2025, Including the COVID ‐19 Pandemic
Background: Acquired demyelinating syndromes (ADS) in children include multiple sclerosis (MS), myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD), aquaporin 4 antibody‐positive neuromyelitis optica spectrum disorder (AQP4+ NMOSD), and other seronegative disorders. We previously reported an increased incidence of overall paediatric ADS and MS between 2007 to 2010 and 2011–2016 (from 0.66 to 0.80 and 0.15 to 0.26 per 100,000 person‐years, respectively). Environmental factors, including viral exposure, may influence these rates. Comparing a recent period that includes the COVID‐19 pandemic provides an opportunity to study temporal patterns. Methods: Children < 18 years with a first demyelinating event between January 2017 and June 2025 were prospectively included in the nationwide PROUDkids 2.0 study or referred to the Dutch Paediatric MS Centre. Diagnoses followed international criteria, and incidence rates were calculated using national population data. Results: Among 257 included children, 111 (43%) had MS, 93 (36%) MOGAD, 5 (2%) AQP4+ NMOSD, and 48 (19%) seronegative ADS. Overall ADS incidence was 0.91 per 100,000 person‐years, with MS 0.40, MOGAD 0.33, AQP4+ NMOSD 0.02, and seronegative ADS 0.16 per 100,000 person‐years. Compared with 2011–2016 (0.26 per 100,000), MS incidence increased, whereas other ADS rates remained stable. MS incidence declined after COVID‐19 restrictions, particularly among adolescents, while MOGAD incidence rose modestly in younger children during the COVID restrictions. Conclusions: Paediatric MS incidence continues to rise in the Netherlands, whereas the incidence of other ADS remains stable. Temporal variations in the incidence of MS and MOGAD during and after the COVID‐19 pandemic may reflect the influence of viral exposure in their pathogenesis.
- Open Access
- 27 October 2022
- Published by Wiley in European Journal of Neurology
- Vol. 30 (11) , 3507-3515
Gut microbiota analysis in pediatric‐onset multiple sclerosis compared to pediatric monophasic demyelinating syndromes and pediatric controls
Background and purpose: Gut microbiota dysbiosis may lead to proinflammatory conditions contributing to multiple sclerosis (MS) etiology. Pediatric‐onset MS patients are close to biological disease onset and less exposed to confounders. Therefore, this study investigated gut microbiota composition and functional pathways in pediatric‐onset MS, compared to monophasic acquired demyelinating syndromes (mADS) and healthy controls (HCs).Methods: Pediatric participants were selected from the Dutch national prospective cohort study including ADS patients and HCs p = 0.015, Shannon/Simpson Diversity Index p = 0.014/p = 0.023), divergent beta diversity (R2 = 3.7%, p = 0.013), and higher abundance of numerous individual resident microbes and functional microbial pathways.Conclusions: Previous results of gut microbiota composition and predicted functional features could not be validated in this Dutch pediatric‐onset MS cohort using a more sensitive 16S pipeline, although it was limited by sample size and DMT use. Notably, several other host‐related factors were found to associate with gut microbiota variation, especially BMI.
- 27 October 2022
- Published by Wiley in European Journal of Neurology
- Vol. 30 (11) , 3507-3515
Open AccessGut microbiota analysis in pediatric‐onset multiple sclerosis compared to pediatric monophasic demyelinating syndromes and pediatric controls
Background and purpose: Gut microbiota dysbiosis may lead to proinflammatory conditions contributing to multiple sclerosis (MS) etiology. Pediatric‐onset MS patients are close to biological disease onset and less exposed to confounders. Therefore, this study investigated gut microbiota composition and functional pathways in pediatric‐onset MS, compared to monophasic acquired demyelinating syndromes (mADS) and healthy controls (HCs).Methods: Pediatric participants were selected from the Dutch national prospective cohort study including ADS patients and HCs p = 0.015, Shannon/Simpson Diversity Index p = 0.014/p = 0.023), divergent beta diversity (R2 = 3.7%, p = 0.013), and higher abundance of numerous individual resident microbes and functional microbial pathways.Conclusions: Previous results of gut microbiota composition and predicted functional features could not be validated in this Dutch pediatric‐onset MS cohort using a more sensitive 16S pipeline, although it was limited by sample size and DMT use. Notably, several other host‐related factors were found to associate with gut microbiota variation, especially BMI.
- Open Access
- 1 May 2021
- Published by Elsevier in Brain and Development
- Vol. 43 (5) , 626-636
Prognostic factors for relapse and outcome in pediatric acute transverse myelitis
- 1 May 2021
- Published by Elsevier in Brain and Development
- Vol. 43 (5) , 626-636
Open AccessPrognostic factors for relapse and outcome in pediatric acute transverse myelitis
- 3 September 2019
- Published by Wolters Kluwer Health in Neurology
- Vol. 93 (10) , E968-E974
Serum neurofilament light chain in pediatric MS and other acquired demyelinating syndromes
Objective To explore the correlation between serum and CSF neurofilament light chain (NfL) and the association of NfL levels and future disease activity in pediatric patients with a first attack of acquired demyelinating syndromes (ADS). Methods In total, 102 children <18 years with a first attack of CNS demyelination and 23 age-matched controls were included. Clinically definite multiple sclerosis (CDMS) was set as an endpoint for analysis. CSF NfL was tested by the commercially available ELISA (UmanDiagnostics); serum NfL (sNfL) was tested with a Simoa assay. Hazard ratios (HR) were calculated with Cox regression analysis. Results Of the 102 patients, 47 (46%) were tested for CSF NfL. CSF and serum NfL correlated significantly in the total group (rho 0.532, p < 0.001) and even more significantly in the subgroup of patients with future CDMS diagnosis (rho 0.773, p < 0.001). sNfL was higher in patients than in controls (geometric mean 6.1 pg/mL, p < 0.001), and was highest in ADS presenting with encephalopathy (acute disseminated encephalomyelitis, n = 28, 100.4 pg/mL), followed by patients without encephalopathy (ADS-) with future CDMS diagnosis (n = 40, 32.5 pg/mL), and ADS- who remained monophasic (n = 34, 17.6 pg/mL). sNfL levels higher than a median of 26.7 pg/mL at baseline are associated with a shorter time to CDMS diagnosis in ADS-(p = 0.045). HR for CDMS diagnosis was 1.09 for each 10 pg/mL increase of sNfL, after correction for age, oligoclonal bands, and MRI measures (p = 0.012). Conclusion The significant correlation between CSF and serum NfL strengthens its reliability as a peripheral marker of neuroaxonal damage. Higher sNfL levels at baseline were associated with higher probability of future CDMS diagnosis in ADS-.
- 3 September 2019
- Published by Wolters Kluwer Health in Neurology
- Vol. 93 (10) , E968-E974
Serum neurofilament light chain in pediatric MS and other acquired demyelinating syndromes
Objective To explore the correlation between serum and CSF neurofilament light chain (NfL) and the association of NfL levels and future disease activity in pediatric patients with a first attack of acquired demyelinating syndromes (ADS). Methods In total, 102 children <18 years with a first attack of CNS demyelination and 23 age-matched controls were included. Clinically definite multiple sclerosis (CDMS) was set as an endpoint for analysis. CSF NfL was tested by the commercially available ELISA (UmanDiagnostics); serum NfL (sNfL) was tested with a Simoa assay. Hazard ratios (HR) were calculated with Cox regression analysis. Results Of the 102 patients, 47 (46%) were tested for CSF NfL. CSF and serum NfL correlated significantly in the total group (rho 0.532, p < 0.001) and even more significantly in the subgroup of patients with future CDMS diagnosis (rho 0.773, p < 0.001). sNfL was higher in patients than in controls (geometric mean 6.1 pg/mL, p < 0.001), and was highest in ADS presenting with encephalopathy (acute disseminated encephalomyelitis, n = 28, 100.4 pg/mL), followed by patients without encephalopathy (ADS-) with future CDMS diagnosis (n = 40, 32.5 pg/mL), and ADS- who remained monophasic (n = 34, 17.6 pg/mL). sNfL levels higher than a median of 26.7 pg/mL at baseline are associated with a shorter time to CDMS diagnosis in ADS-(p = 0.045). HR for CDMS diagnosis was 1.09 for each 10 pg/mL increase of sNfL, after correction for age, oligoclonal bands, and MRI measures (p = 0.012). Conclusion The significant correlation between CSF and serum NfL strengthens its reliability as a peripheral marker of neuroaxonal damage. Higher sNfL levels at baseline were associated with higher probability of future CDMS diagnosis in ADS-.
- Open Access
- 22 March 2018
- Published by Springer Nature in Journal of Neurology
- Vol. 265 (6) , 1310-1319
Incidence and outcome of acquired demyelinating syndromes in Dutch children: update of a nationwide and prospective study
Introduction Acquired demyelinating syndromes (ADS) are immune-mediated demyelinating disorders of the central nervous system in children. A nationwide, multicentre and prospective cohort study was initiated in the Netherlands in 2006, with a reported ADS incidence of 0.66/100,000 per year and MS incidence of 0.15/100,000 per year in the period between 2007 and 2010. In this study, we provide an update on the incidence and the long-term follow-up of ADS in the Netherlands. Methods Children < 18 years with a first attack of demyelination were included consecutively from January 2006 to December 2016. Diagnoses were based on the International Paediatric MS study group consensus criteria. Outcome data were collected by neurological and neuropsychological assessments, and telephone call assessments. Results Between 2011 and 2016, 55/165 of the ADS patients were diagnosed with MS (33%). This resulted in an increased ADS and MS incidence of 0.80/100,000 per year and 0.26/100,000 per year, respectively. Since 2006 a total of 243 ADS patients have been included. During follow-up (median 55 months, IQR 28–84), 137 patients were diagnosed with monophasic disease (56%), 89 with MS (37%) and 17 with multiphasic disease other than MS (7%). At least one form of residual deficit including cognitive impairment was observed in 69% of all ADS patients, even in monophasic ADS. An Expanded Disability Status Scale score of ≥ 5.5 was reached in 3/89 MS patients (3%). Conclusion The reported incidence of ADS in Dutch children has increased since 2010. Residual deficits are common in this group, even in monophasic patients. Therefore, long-term follow-up in ADS patients is warranted.
- 22 March 2018
- Published by Springer Nature in Journal of Neurology
- Vol. 265 (6) , 1310-1319
Open AccessIncidence and outcome of acquired demyelinating syndromes in Dutch children: update of a nationwide and prospective study
Introduction Acquired demyelinating syndromes (ADS) are immune-mediated demyelinating disorders of the central nervous system in children. A nationwide, multicentre and prospective cohort study was initiated in the Netherlands in 2006, with a reported ADS incidence of 0.66/100,000 per year and MS incidence of 0.15/100,000 per year in the period between 2007 and 2010. In this study, we provide an update on the incidence and the long-term follow-up of ADS in the Netherlands. Methods Children < 18 years with a first attack of demyelination were included consecutively from January 2006 to December 2016. Diagnoses were based on the International Paediatric MS study group consensus criteria. Outcome data were collected by neurological and neuropsychological assessments, and telephone call assessments. Results Between 2011 and 2016, 55/165 of the ADS patients were diagnosed with MS (33%). This resulted in an increased ADS and MS incidence of 0.80/100,000 per year and 0.26/100,000 per year, respectively. Since 2006 a total of 243 ADS patients have been included. During follow-up (median 55 months, IQR 28–84), 137 patients were diagnosed with monophasic disease (56%), 89 with MS (37%) and 17 with multiphasic disease other than MS (7%). At least one form of residual deficit including cognitive impairment was observed in 69% of all ADS patients, even in monophasic ADS. An Expanded Disability Status Scale score of ≥ 5.5 was reached in 3/89 MS patients (3%). Conclusion The reported incidence of ADS in Dutch children has increased since 2010. Residual deficits are common in this group, even in monophasic patients. Therefore, long-term follow-up in ADS patients is warranted.
- 14 February 2018
- Published by Wiley in European Journal of Neurology
- Vol. 25 (5) , 782-786
Paediatric acute disseminated encephalomyelitis followed by optic neuritis: disease course, treatment response and outcome
Background and purpose: Acute disseminated encephalomyelitis followed by optic neuritis (ADEM‐ON) is a rare demyelinating syndrome that is different from multiple sclerosis and neuromyelitis optica spectrum disorder. The aim of this study was to describe the disease course, treatment response and outcome of children with ADEM‐ON.Methods: Children of 10 mg/day. Visual and cognitive residual deficits were common in this group.Conclusions: Acute disseminated encephalomyelitis followed by optic neuritis is an anti‐MOG antibody‐associated relapsing disorder that can have a heterogeneous disease course. Patients were refractory for maintenance immunosuppression and appeared to be corticosteroid‐dependent. Further international collaborations are now required to unify guidelines in this difficult‐to‐manage group of patients.
- 14 February 2018
- Published by Wiley in European Journal of Neurology
- Vol. 25 (5) , 782-786
Paediatric acute disseminated encephalomyelitis followed by optic neuritis: disease course, treatment response and outcome
Background and purpose: Acute disseminated encephalomyelitis followed by optic neuritis (ADEM‐ON) is a rare demyelinating syndrome that is different from multiple sclerosis and neuromyelitis optica spectrum disorder. The aim of this study was to describe the disease course, treatment response and outcome of children with ADEM‐ON.Methods: Children of 10 mg/day. Visual and cognitive residual deficits were common in this group.Conclusions: Acute disseminated encephalomyelitis followed by optic neuritis is an anti‐MOG antibody‐associated relapsing disorder that can have a heterogeneous disease course. Patients were refractory for maintenance immunosuppression and appeared to be corticosteroid‐dependent. Further international collaborations are now required to unify guidelines in this difficult‐to‐manage group of patients.
- 1 March 2017
- Published by Elsevier in European Journal of Paediatric Neurology
- Vol. 21 (2) , 300-304
Evolution of MRI abnormalities in paediatric acute disseminated encephalomyelitis
- 1 March 2017
- Published by Elsevier in European Journal of Paediatric Neurology
- Vol. 21 (2) , 300-304
Evolution of MRI abnormalities in paediatric acute disseminated encephalomyelitis